| Identification | Back Directory | [Name]
XC-302 free base | [CAS]
916890-10-3 | [Synonyms]
XC302
XC-302
XC 302
Puquitinib
XC-302 free base
XC 302 free base,XC302 free base
9H-Purine-2,6-diamine, N6-cyclopropyl-N2-6-quinolinyl- | [Molecular Formula]
C17H15N7 | [MOL File]
916890-10-3.mol | [Molecular Weight]
317.36 |
| Hazard Information | Back Directory | [Uses]
Puquitinib (XC-302 free base) is a multi-target inhibitor with the activity of inducing autophagy in nasopharyngeal carcinoma cells by inhibiting the PI3K/AKT/mTOR signaling pathway. Puquitinib was able to inhibit the proliferation of CNE-2 cells, showing a dose-dependent antiproliferative effect. Puquitinib induced the formation of autophagosomes and autolysosomes in CNE-2 cells, which were observed by fluorescence microscopy and electron microscopy. Puquitinib promoted the formation of LC3-II and increased the expression of beclin 1, while reducing the level of p62. Puquitinib inhibited the PI3K/AKT/mTOR pathway by reducing the expression of p-AKT and p-mTOR. Puquitinib also induced apoptosis in CNE-2 cells, and when autophagy was inhibited, the apoptosis rate was reduced, which means that autophagy may interact with apoptosis to induce cell death[1]. | [References]
[1] Puquitinib mesylate (XC-302) induces autophagy via inhibiting the PI3K/AKT/mTOR signaling pathway in nasopharyngeal cancer cells DOI:10.3892/ijmm.2015.2378 |
|
|